Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Data availability The data supporting this study are available from the corresponding author on reasonable request
A major development in diabetes care has just emerged and it could have a meaningful impact on younger patients.Novo Nordisk has reported that its oral GLP-1 drug significantly reduced blood sugar levels in children and adolescents with type 2 diabetes, successfully meeting the main goal of a late-stage clinical trial.This is a space where treatment options are still relatively limited so any progress here is worth paying attention to
References: Tian, Q., Song, Y., Deng, Y., Lin, S
cardiovascular disease
US$ 27.21
US$ 20.80
US$ 25.02
